2011-11-15T15:22:01-06:00 2010-12-31 LARSONALLEN LLP 2900 SOUTH QUINCY ST SUITE 150 ARLINGTON VA 22206 990 2010-01-01 521224577 BIOTECHNOLOGY INDUSTRY ORGANIZATION BIOT 2029629200 1201 MARYLAND AVE SW NO 900 WASHINGTON DC 20024 A SCOTT WHITAKER 2029629200 2011-11-15 1 KAREN GRIES 7039985100 2010 2016-03-07 17:11:31Z JAMES C GREENWOOD 1201 MARYLAND AVE SW NO 900 WASHINGTON DC 20024 124430495 0 X WWW.BIO.ORG X 1993 DC BIOTECHNOLOGY RESEARCHERS EXPAND THE BOUNDARIES OF SCIENCE TO BENEFIT MANKIND BY PROVIDING BETTER HEALTHCARE, ENHANCED AGRICULTURE, AND A CLEANER AND SAFER ENVIRONMENT. THE MISSION OF BIO IS TO BE THE CHAMPION OF BIOTECHNOLOGY AND THE ADVOCATE FOR ITS MEMBER ORGANIZATIONS - BOTH LARGE AND SMALL. 109 109 182 109 271792 0 0 0 55354873 57498909 1356296 3478235 301100 42100 57012269 61019244 0 0 0 0 24221558 23396161 0 0 0 39174981 35354014 63396539 58750175 -6384270 2269069 61748284 65414013 25354585 26464995 36393699 38949018 X THE BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) REPRESENTS MORE THAN 1,100 COMPANIES AND ORGANIZATIONS IN WASHINGTON DC, STATE CAPITALS, AND INTERNATIONAL FORA. BIOTECHNOLOGY INDUSTRY ORGANIZATION IS FOUNDED ON THE PRINCIPLE THAT POLICY MUST NURTURE INNOVATION IN THE LIFE SCIENCES TO OVERCOME CHALLENGES IN HEALTH, AGRICULTURE, INDUSTRY, AND THE ENVIRONMENT. OUR MEMBERS REPRESENT COMPANIES OFFERING A SPECTRUM OF BIOTECHNOLOGY APPLICATIONS ACROSS MAJOR SECTORS OF THE ECONOMY. BIOTECHNOLOGY INDUSTRY ORGANIZATION MEMBERS ALSO INCLUDE UNIVERSITIES, NONPROFITS, PATIENT GROUPS, AND OTHER ORGANIZATIONS THAT PLAY AN IMPORTANT ROLE IN THE FUTURE OF THE LIFE SCIENCES. BIOTECHNOLOGY INDUSTRY ORGANIZATION'S ACTIVITIES ARE BROKEN DOWN INTO TWO PROGRAMS - ADVOCACY AND SERVICES. 0 0 ADVOCACYBIOTECHNOLOGY INDUSTRY ORGANIZATION'S ADVOCACY EFFORTS REFLECT THE PRIORITIES IDENTIFIED BY THE BIOTECHNOLOGY INDUSTRY ORGANIZATION BOARD OF DIRECTORS AND THE FOUR SECTION GOVERNING BOARDS.THE BOARD OF DIRECTORS FOCUSES ON ISSUES OF IMPORTANCE TO ALL BIOTECHNOLOGY INDUSTRY ORGANIZATION MEMBERS, REGARDLESS OF THEIR SIZE OR TECHNOLOGY. THESE CROSS-CUTTING ADVOCACY ACCOMPLISHMENTS IN 2010 ARE LISTED BELOW. - SAFEGUARDED AND ADVANCED INTELLECTUAL PROPERTY PROTECTIONS, DOMESTICALLY AND INTERNATIONALLY.- FOSTERED A DIALOGUE ABOUT ETHICS AND PROACTIVELY ADVANCED THE SOCIALLY RESPONSIBLE USE OF BIOTECHNOLOGY.- PROMOTED INVESTMENT IN GOVERNMENT AND ACADEMIC RESEARCH.- EXPANDED OUTREACH TO FOREIGN GOVERNMENTS AND ENTITIES TO EDUCATE ON POLICY ISSUES OF IMPORTANCE TO THE BIOTECHNOLOGY INDUSTRY AND TO IMPROVE THE INVESTMENT AND REGULATORY CLIMATE FOR BIOTECH PRODUCTS.THE EMERGING COMPANIES SECTION PRESSES FOR RULES FAVORABLE TO SMALL COMPANIES IN AREAS SUCH AS TAX POLICY, FINANCIAL REPORTING AND ACCOUNTING LAW AND REGULATIONS, AND FEDERAL GRANTS. THE EMERGING COMPANIES SECTION'S 2010 ADVOCACY ACCOMPLISHMENTS ARE LISTED BELOW.- ADVANCED THE INTEREST OF EMERGING COMPANIES IN CAPITAL FORMATION AND FINANCIAL SERVICES POLICY.- INCREASED OPPORTUNITIES FOR SMALL COMPANIES TO RECEIVE FEDERAL GRANTS.- ADVOCATED FOR TAX POLICY SUPPORTING INNOVATIVE EMERGING COMPANIES.- ADVOCATED FOR THE REMOVAL OF BURDENSOME FINANCIAL REPORTING REGULATIONS.- INFLUENCED HEALTH CARE POLICY TO REFLECT THE CONCERNS OF SMALL BIOTECHNOLOGY COMPANIES.THE FOOD & AGRICULTURE SECTION FOCUSES ON MAINTAINING A SCIENCE-BASED REGULATORY ENVIRONMENT FOR BIOTECH CROPS AND EMERGING PRODUCTS, SUCH AS PLANT- AND ANIMAL-MADE PHARMACEUTICALS AND FEEDSTOCKS FOR BIOFUELS. SOME OF THE FOOD AND AGRICULTURE SECTION'S 2010 ADVOCACY ACCOMPLISHMENTS ARE LISTED BELOW.- SHORED UP FDA POLICY ON LABELING OF AGRICULTURAL PRODUCTS DERIVED FROM BIOTECHNOLOGY.- COORDINATED ADVOCACY RESULTING IN JAPAN FIXING ITS STALLED REGULATORY PROCESS.- ADVOCATED FOR STRONG U.S. GOVERNMENT OUTREACH TO OTHER COUNTRIES IN SUPPORT OF INDUSTRY POSITIONS FOR THE BIOSAFETY PROTOCOL.-ADVOCATED FOR STRONG U.S. GOVERNMENT ENGAGEMENT WITH EU ON PLANT AND ANIMAL BIOTECHNOLOGY.-SUCCESSFULLY OUTREACHED STAKEHOLDERS ON BENEFITS AND USES OF BIOTECHNOLOGY INCLUDING THROUGH STEWARDSHIP PROGRAMS.-PUBLIC RECOGNITION BY KEY APPOINTEES AT USDA AND STATE DEPARTMENT FOR BIOTECHNOLOGY'S CONTRIBUTIONS TO SUSTAINABLE AGRICULTURE.THE HEALTH SECTION DRIVES ADVOCACY TO ENSURE THAT PATIENTS HAVE ACCESS TO THE FRUITS OF BIOTECH RESEARCH, WHILE MAINTAINING THE MARKETPLACE REWARDS THAT DRIVE CONTINUED INNOVATION. BELOW ARE THE HEALTH SECTION'S 2010 ACCOMPLISHMENTS.- IMPROVED THE U.S. FOOD AND DRUG ADMINISTRATION'S (FDA'S) PROCESS FOR HUMAN DRUG REVIEW.- ENHANCED PATIENT ACCESS TO INNOVATIVE THERAPIES.- ENSURED THAT BIOSIMILARS POLICIES PROTECT PATIENT SAFETY AND PROMOTE BIOMEDICAL INNOVATION.- PROMOTED DEVELOPMENT AND USE OF RESEARCH TOOLS, MOLECULAR DIAGNOSTICS AND PERSONALIZED THERAPIES.- ADVOCATED FOR POLICIES THAT FOSTER VACCINE INNOVATION AND PROMOTE PANDEMIC AND BIO-DEFENSE PREPAREDNESS.- IMPROVED THE INTERNATIONAL ENVIRONMENT FOR BIOMEDICAL INNOVATION.THE INDUSTRIAL & ENVIRONMENTAL SECTION ADVOCATES FOR INCENTIVES THAT HELP CREATE MARKET DEMAND FOR CUTTING-EDGE CONSUMER PRODUCTS SUCH AS GREEN PLASTICS, RENEWABLE FUELS AND CHEMICALS AND HEALTHIER FOODS. BELOW ARE THE INDUSTRIAL & ENVIRONMENTAL SECTION'S 2010 ADVOCACY ACCOMPLISHMENTS.BIOFUELS- ADVOCATED FOR GRANTS AND LOAN GUARANTEES ISSUED TO ADVANCED AND CELLULOSIC BIOFUELS PROJECTS.- ADVANCED BIOFUELS TAX PACKAGE INTRODUCED IN HOUSE (HR 5142) WITH 50+ COSPONSORS. - HELPED SECURE A STRONG BIOMASS CROP ASSISTANCE PROGRAM FINAL RULE.- ADVOCATED FOR PROGRESS ON USDA AND DOE LOAN GUARANTEES.- ADVOCATED FOR MODIFICATION TO RENEWABLE FUEL STANDARD FINAL RULE.BIOBASED PRODUCTS- EDUCATED CONGRESS ON THE DRAFT BIOBASED TAX LEGISLATION AND ITS IMPACT ON JOB CREATION AND GROWING THE U.S. CHEMICAL INDUSTRY.BIO HOLDS TWO INDUSTRIAL BIOTECH CONFERENCES EACH YEAR; THE WORLD CONGRESS ON INDUSTRIAL BIOTECHNOLOGY AND BIOPROCESSING, AND THE PACIFIC RIM SUMMIT ON INDUSTRIAL BIOTECHNOLOGY AND BIOENERGY.THE PACIFIC RIM SUMMIT ON INDUSTRIAL BIOTECHNOLOGY & BIOENERGY WAS HELD IN DECEMBER 2010 IN HONOLULU, HI, AND HAD 355 ATTENDEES. THE SUMMIT IS WHERE "EAST MEETS WEST" IN THE RAPIDLY EXPANDING APPLICATION OF INDUSTRIAL BIOTECHNOLOGY. THE CONFERENCE HIGHLIGHTS RECENT ADVANCES IN BIOTECHNOLOGY FOR BIOENERGY, RENEWABLE CHEMICALS, MICROBIOLOGY, ENZYMES, BIOBASED PRODUCTS, ENERGY CROPS, MARINE BIOTECH, SYNTHETIC BIOLOGY, MANUFACTURING AND PROCESSING. TECHNICAL TRACKS, PLENARY SESSIONS AND PRIVATE ONE-ON-ONE BUSINESS PARTNERING MEETINGS ARE HELD DURING THE CONFERENCE. THE WORLD CONGRESS ON INDUSTRIAL BIOTECHNOLOGY & BIOPROCESSINGWAS HELD N MAY 2010 IN WASHINGTON, D.C., WITH 950 ATTENDEES. THIS CONFERENCE IS A INTERDISCIPLINARY FORUM PRESENTING THE LATEST DEVELOPMENTS IN INDUSTRIAL BIOTECHNOLOGY FOR ADVANCED BIOFUELS, RENEWABLE CHEMICALS, BIOBASED MATERIALS, AND BIOTECH-BASED MANUFACTURING AND PROCESSING. IT INCLUDES TECHNICAL TRACKS, PLENARY SESSIONS, INVESTOR SESSIONS AND PRIVATE ONE-ON-ONE BUSINESS PARTNERING MEETINGS. SERVICESBIOTECHNOLOGY INDUSTRY ORGANIZATION'S SERVICES INCLUDE CONFERENCES AND ACTIVITIES THAT BRING TOGETHER INDUSTRY PARTNERS AND INVESTORS FOR EVENTS RANGING FROM THE BIOTECHNOLOGY INDUSTRY ORGANIZATION INTERNATIONAL CONVENTION TO PROFESSIONAL DEVELOPMENT CONFERENCES FOR HUMAN RESOURCES AND BUSINESS DEVELOPMENT EXECUTIVES. BIOTECHNOLOGY INDUSTRY ORGANIZATION INTERNATIONAL CONVENTION - THE 2010 BIO INTERNATIONAL CONVENTION WAS HELD AT MCCORMICK PLACE IN CHICAGO, IL ON MAY 3-6, 2010. THE EVENT HOSTED MORE THAN 15,000 ATTENDEES FROM 65 COUNTRIES, AND 49 U.S. STATES. THE CONVENTION CONTINUED TO DRAW OVER 30% OF THE ATTENDANCE FROM COUNTRIES OUTSIDE THE U.S. WHICH INCLUDES MORE THAN 80 INTERNATIONAL PUBLIC OFFICIALS INCLUDING MINISTERS OF SCIENCE, AGRICULTURE, AND TECHNOLOGY.THE KEY ELEMENTS OF THE BIOTECHNOLOGY INDUSTRY ORGANIZATION INTERNATIONAL CONVENTION WERE:- EDUCATIONAL PROGRAMMING THAT INCLUDED FOUR DAYS WITH 170 BREAKOUT SESSIONS, 17 EDUCATIONAL TRACKS, MORE THAN 1,000 SPEAKERS, 2 KEYNOTE SESSIONS AND FIVE SUPER SESSIONS.- BIOTECHNOLOGY INDUSTRY ORGANIZATION BUSINESS FORUM WHERE 3,500 BUSINESS LEADERS FROM 2,125 COMPANIES PARTICIPATED IN MORE THAN 17,000 ONE-ON-ONE PARTNERING MEETINGS. (ALSO LISTED BELOW.) - BIOTECHNOLOGY INDUSTRY ORGANIZATION EXHIBITION HOSTED APPROXIMATELY 1,700 COMPANIES AT MCCORMICK PLACE WITH 180,000 NET SQUARE FEET OF EXHIBIT SPACE. ATTENDEES MINGLED AMONG THE 73 STATE, COUNTRY AND REGIONAL PAVILIONS AND ALSO THE 8 PRODUCT FOCUS ZONES.- PROFESSIONAL NETWORKING TOOK PLACE THROUGHOUT THE CONVENTION DURING THREE LARGE GENERAL EVENTS (WELCOME, EXHIBITION HOSPITALITY AND GALA), AS WELL AS SEVEN INVITE-ONLY RECEPTIONS (BIOTECHNOLOGY INDUSTRY ORGANIZATION BOARD OF DIRECTORS & 2010 STEERING COMMITTEE, CEO & HEALTH ADVOCATES, PUBLIC OFFICIALS, INVESTOR & BUSINESS DEVELOPMENT, BUSINESS FORUM, GLOBAL FOOD & AGRICULTURE, AND CEO.) CAPITAL FORMATION & BUSINESS DEVELOPMENT - THROUGH A PORTFOLIO OF EVENTS, BIOTECHNOLOGY INDUSTRY ORGANIZATION SUPPORTS THE CAPITAL FORMATION AND BUSINESS DEVELOPMENT NEEDS OF HUNDREDS OF SMALL, INNOVATIVE COMPANIES THAT FORM THE BASIS OF THE BIOTECHNOLOGY INDUSTRY. THESE PROGRAMS FACILITATE CRITICAL CAPITAL FORMATION AND PARTNERSHIPS, AND PROVIDE PROFESSIONAL SERVICES. THROUGHOUT THE YEAR, BIOTECHNOLOGY INDUSTRY ORGANIZATION HOSTS OR CO-HOSTS NINE NATIONAL AND INTERNATIONAL CONFERENCES THAT PROVIDE VENUES FOR MEMBER AND NON-MEMBER COMPANIES TO PRESENT NEW DATA, MEET AND PARTNER WITH FELLOW BIOTECH COMPANIES, AND ATTRACT FUNDING FROM INVESTORS AND OTHER ORGANIZATIONS. THESE 2010 CONFERENCES BELOW SERVED MORE THAN 12,000 MEMBER AND NON-MEMBER ATTENDEES, AND INCLUDED MORE THAN 30,000 PARTNERING MEETINGS AND 950 COMPANY PRESENTATIONS OVER 10 DAYS OF OFFICIAL PROGRAMMING. THE 2010 U.S. PROGRAM INCLUDED: - BIOTECHNOLOGY INDUSTRY ORGANIZATION CEO & INVESTOR CONFERENCE, NEW YORK CITY, NY, FEBRUARY 8-9- BIOTECHNOLOGY INDUSTRY ORGANIZATION - WINDHOVER, NEW YORK CITY, NY, FEBRUARY 23-25- BUSINESS FORUM AT THE BIOTECHNOLOGY INDUSTRY ORGANIZATION INTERNATIONAL CONVENTION, CHICAGO, IL, MAY 4-6- BIOTECHNOLOGY INDUSTRY ORGANIZATION INVESTOR FORUM, SAN FRANCISCO, CA, OCTOBER 5-7BIO ALSO ORGANIZES, HOSTS, OR ASSISTS WITH HOSTING, FIVE OF THE LARGEST BIOTECH MEETINGS OUTSIDE OF THE U.S.; THE 2010 THE PROGRAM INCLUDED:- BIOTECHNOLOGY INDUSTRY ORGANIZATION -ASIA, TOKYO, JAPAN, JANUARY 25-26- BIOTECHNOLOGY INDUSTRY ORGANIZATION -EUROPE SPRING, BARCELONA, SPAIN, APRIL 8-10- BIOTECHNOLOGY INDUSTRY ORGANIZATION INDIA, HYDERABAD, INDIA, SEPTEMBER 21-22- BIOTECHNOLOGY INDUSTRY ORGANIZATION -EUROPE FALL, MUNICH, GERMANY, NOVEMBER 15-17IN 2010, BIOTECHNOLOGY INDUSTRY ORGANIZATION ALSO PROVIDED COST-EFFECTIVE EDUCATIONAL PROGRAMS TO HELP EXECUTIVES FROM SMALL COMPANIES. THESE WORKSHOPS, FOCUSED ON EXECUTIVE PRESENTATION SKILLS AND BASIC AND ADVANCED BUSINESS DEVELOPMENT SKILLS, WERE HELD THROUGHOUT THE YEAR IN VARIOUS LOCATIONS AROUND THE US AND GERMANY.HUMAN RESOURCES - IN 2010, THE ANNUAL BIOTECHNOLOGY INDUSTRY ORGANIZATION HUMAN RESOURCES CONFERENCE WAS HOSTED IN CHICAGO, IL ON MAY 5-7 IN CONJUNCTION WITH THE BIOTECHNOLOGY INDUSTRY ORGANIZATION INTERNATIONAL CONVENTION. IN ATTENDANCE WERE APPROXIMATELY 150 HUMAN RESOURCES PROFESSIONALS TO LEARN ABOUT TRENDS IN COMPENSATION, RETENTION, EMPLOYMENT, RECRUITMENT AND TO BUILD AND EXPAND THEIR EXPERTISE IN THE TECHNICAL AND BUSINESS AREAS OF THEIR PROFESSION. 0 0 1 1 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 166 0 1 182 1 1 1 1 IN 0 0 0 0 X 109 109 1 0 1 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X A SCOTT WHITAKER 2029629200 1201 MARYLAND AVENUE SW STE 900 WASHINGTON DC 20024 BEEMAN DONALD 5.00 X 0 0 0 BIENAIME JEAN-JACQUES 5.00 X 0 0 0 BOGER JOSHUA 5.00 X 0 0 0 BONANNI FABRIZIO 5.00 X X 0 0 0 BORISY ALEXIS 5.00 X 0 0 0 BORMANN BJ 5.00 X 0 0 0 CLARK IAN 5.00 X 0 0 0 COHEN RON 5.00 X X 0 0 0 COLES N 5.00 X 0 0 0 CONWAY ROBERT 5.00 X 0 0 0 CROWLEY JOHN 5.00 X 0 0 0 DE RUITER TJERK 5.00 X X 0 0 0 DEBETHIZY J DONALD 5.00 X 0 0 0 DOERFLER DOUGLAS 5.00 X 0 0 0 DUNCAN GREG 5.00 X 0 0 0 DUNSIRE DEBORAH 5.00 X 0 0 0 ECKES PETER 5.00 X 0 0 0 EGGERT CHARLES 5.00 X 0 0 0 ELLERBUSCH SUSAN 5.00 X 0 0 0 ENGLE STEVEN 5.00 X 0 0 0 ENO RICHARD 5.00 X 0 0 0 FIROUZ FEREYDOUN 5.00 X 0 0 0 FISCHER PAUL 5.00 X 0 0 0 FRITZ CAROLYN 5.00 X 0 0 0 GATTO STEPHEN 5.00 X 0 0 0 GERBERDING JULIE 5.00 X 0 0 0 GERMANO GENO 5.00 X 0 0 0 GOLD MITCHELL 5.00 X 0 0 0 GORMLEY GLENN 5.00 X 0 0 0 GOWEN MAXINE 5.00 X 0 0 0 GREENLEAF PETER 5.00 X 0 0 0 GRUBER PATRICK 5.00 X 0 0 0 GUTTERSON NEAL 5.00 X 0 0 0 HALE DAVID 5.00 X 0 0 0 HA-NGOC TUAN 5.00 X 0 0 0 HASTINGS PAUL 5.00 X 0 0 0 HERNDON RUSSELL 5.00 X 0 0 0 HOPPENOT HERV 5.00 X 0 0 0 JUNIUS DANIEL 5.00 X 0 0 0 KAILIAN VAUGHN 5.00 X 0 0 0 KARSEN PERRY 5.00 X 0 0 0 KING RACHEL 5.00 X 0 0 0 KOENIG SCOTT 5.00 X 0 0 0 KUENKER KAY 5.00 X 0 0 0 LEAHY EMER 5.00 X 0 0 0 LEFF JONATHAN 5.00 X 0 0 0 LEFTEROFF TRACY 5.00 X 0 0 0 LEONARD JOHN 5.00 X 0 0 0 LUNDBERG JAN 5.00 X 0 0 0 MARAGANORE JOHN 5.00 X 0 0 0 MATHERS THOMAS 5.00 X 0 0 0 MCCAULEY GORDON 5.00 X 0 0 0 MEDFORD RUSSELL 5.00 X 0 0 0 MEEKER DAVID 5.00 X 0 0 0 MENDELSON ALAN 5.00 X 0 0 0 MENTO STEVEN 5.00 X 0 0 0 MILLIGAN JOHN 5.00 X 0 0 0 MOCH KENNETH 5.00 X 0 0 0 MONROE ADAM 5.00 X 0 0 0 MORGAN DAVID 5.00 X 0 0 0 MORRIS ARLENE 5.00 X 0 0 0 MYERS DAN 5.00 X 0 0 0 NELSEN LITA 5.00 X 0 0 0 NICHTBERGER STEVEN 5.00 X 0 0 0 NICOLAIDES NICHOLAS 5.00 X 0 0 0 OKARMA THOMAS 5.00 X 0 0 0 PAKIANATHAN DEEPA 5.00 X 0 0 0 PARKINSON ROBERT 5.00 X 0 0 0 PAYA CARLOS 5.00 X 0 0 0 PELTZ STUART 5.00 X 0 0 0 PETERSON KRISTINE 5.00 X 0 0 0 PISANO WAYNE 5.00 X 0 0 0 POPS RICHARD 5.00 X 0 0 0 PREUSS DAPHNE 5.00 X 0 0 0 PURCELL DENNIS 5.00 X 0 0 0 PYOTT DAVID 5.00 X 0 0 0 RANIERI JOHN 5.00 X 0 0 0 RHODES WILLIAM 5.00 X 0 0 0 RIVA CARLOS 5.00 X 0 0 0 ROBIN HOWARD 5.00 X 0 0 0 RODELL TIMOTHY 5.00 X 0 0 0 ROWE JEFF 5.00 X 0 0 0 RYDER STEVEN 5.00 X 0 0 0 SANDS ARTHUR 5.00 X 0 0 0 SAPIRSTEIN JAMES 5.00 X 0 0 0 SCHNEIDER JOACHIM 5.00 X X 0 0 0 SCHULZE GAIL 5.00 X 0 0 0 SHAW ALAN 5.00 X 0 0 0 SHERWIN STEPHEN 5.00 X X 0 0 0 SIEGEL JAY 5.00 X 0 0 0 SKALETSKY MARK 5.00 X X 0 0 0 SKURLA JOSEPH 5.00 X 0 0 0 STANDLEE CHRISTOPHER 5.00 X 0 0 0 STEINER GERALD 5.00 X 0 0 0 STOTISH RONALD 5.00 X 0 0 0 STRAHLMAN ELLEN 5.00 X 0 0 0 SULLIVAN EDDIE 5.00 X 0 0 0 THAKRAR ATUL 5.00 X 0 0 0 TUTTLE STEVEN 5.00 X 0 0 0 VAN BOKKELEN GIL 5.00 X 0 0 0 VAN WART HAROLD 5.00 X 0 0 0 VERBRUGGEN MARC 5.00 X 0 0 0 WATKINS H THOMAS 5.00 X X 0 0 0 WELLS BARBARA 5.00 X 0 0 0 WELSH HUGH 5.00 X 0 0 0 WOLFSON JONATHAN 5.00 X 0 0 0 WONG MARK 5.00 X 0 0 0 ZAKES BRADFORD 5.00 X 0 0 0 ZERBE ROBERT 5.00 X 0 0 0 GREENWOOD JAMES 40.00 X 1159064 0 397922 MURPHY EARLY LISA 40.00 X 482949 0 41078 WHITAKER A SCOTT 40.00 X 682980 0 49742 DILENGE THOMAS 40.00 X 465415 0 50663 EISENBERG ALAN 40.00 X 494017 0 50393 DEL MONTE BRENT 40.00 X 441204 0 41964 ERICKSON BRENT 40.00 X 376377 0 48853 BOMER SHARON 40.00 X 273969 0 51581 JOSEPH JEFFREY 40.00 X 382480 0 47384 FINAN AMY 40.00 X 334340 0 42467 LYCETT ROBERTA 40.00 X 328815 0 46684 RADCLIFFE SARA 40.00 X 345866 0 42119 DARRAGH SEAN 40.00 X 409220 0 50552 KELLY PATRICK 40.00 X 307195 0 45306 DENNIS SANDRA 40.00 X 277504 0 45444 SAUER HANSJORG 40.00 X 259671 0 43431 MCHUGH PETER 40.00 X 221653 0 42809 7242719 0 1138392 66 0 1 0 FREEMAN COMPANIES 1600 VICEROY SUITE 100 DALLAS TX 75247 CONVENTION & CONFERENCES SERVICES 1635358 PROJECTION INC PO BOX 890472 CHARLOTTE NC 282890472 VIDEO SERVICES 1005439 FIXATION MARKETING 4340 EAST-WEST HWY SUITE 200 BETHESDA MD 208144411 MARKETING 949697 RHODE PLANNING & MGMT SOLUTIONS INC 42 LADD STREET SUITE 302 EAST GREENWICH RI 02818 TRANSPORTATION SERVICES 450044 HOGAN & LOVELLS LLP 555 THIRTEENTH ST NW WASHINGTON DC 200041109 LEGAL SERVICES 415973 64 CONFERENCE/MEETING REV 541800 32481586 32228325 253261 MEMBERSHIP DUES 900099 22182487 22182487 BUSINESS SOLUTIONS 900099 2815963 2815963 PUBLICATION ADVERTISIN 541800 18873 342 18531 57498909 1607679 1607679 64338691 943116 62410761 1000490 1927930 -57374 1870556 1870556 INTERNET REVENUES 900099 42100 42100 42100 61019244 54453254 271792 6294198 6678329 13759284 634398 1337283 986867 249108 73117 2986109 278820 5437708 236121 1853258 3783592 1042596 15899936 4782 1102863 1186298 OUTREACH 618392 PUBLIC RELATIONS 278432 BAD DEBT EXPENSE 195506 SALES & TAX 91068 MISCELLANEOUS 20880 15428 58750175 11568885 6979800 1298340 1805535 1733438 2907323 11437276 6585164 5443048 4852112 41123212 48535212 581361 334031 61748284 65414013 6922038 8055493 11870408 12037740 6562139 6371762 25354585 26464995 X 36393699 38949018 36393699 38949018 61748284 65414013 X 2269069 286250 X 0 1 1 X 0 1000 1000 1000 1 FRIENDS OF MARTIN O'MALLEY 218 E LEXINGTON STREET SUITE 602 BALTIMORE MD 21202 521677368 1000 0 0 1 22182487 8440000 3731 8443731 8429345 14386 ORGANIZATIONS DIRECT AND INDIRECT POLITICAL CAMPAIGN ACTIVITIES: PART I-A, LINE 1: CONTRIBUTION TO STATE CAMPAIGN IN SUPPORT OF CANDIDATE. 7882920 3791737 4091183 3554356 2793427 760929 4852112 CAPITAL LEASE OBLIGATION 116172 DEFERRED RENT 6255590 6371762 61019244 58750175 2269069 151633 134617 286250 2555319 61614860 151633 665429 817062 60797798 278820 -57374 221446 61019244 59059541 588186 588186 58471355 278820 278820 58750175 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X: THE ORGANIZATION IS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(6) OF THE INTERNAL REVENUE CODE AS A SECTION 501(A) ORGANIZATION. HOWEVER, THE ORGANIZATION IS SUBJECT TO FEDERAL AND DISTRICT OF COLUMBIA TAXES ON ITS UNRELATED BUSINESS INCOME. THE ORGANIZATION ADOPTED THE INCOME TAX STANDARD FOR UNCERTAIN INCOME TAX POSITIONS. THE ORGANIZATION EVALUATED ITS TAX POSITIONS AND DETERMINED THAT ITS TAX POSITIONS ARE MORE-LIKELY-THAN-NOT TO BE SUSTAINED ON EXAMINATION. THE ORGANIZATION'S TAX RETURNS ARE SUBJECT TO REVIEW AND EXAMINATION BY FEDERAL, STATE AND LOCAL AUTHORITIES. THE TAX RETURNS FOR THE FISCAL YEARS ENDED 2007 TO 2009 ARE OPEN FOR EXAMINATION BY FEDERAL, STATE AND LOCAL AUTHORITIES. PART XI, LINE 8 - OTHER ADJUSTMENTS: CBI REVENUE 53,903. CBI LOBBYING FUND REVENUE 425,500. FOOD & AG INITIATIVES REVENUE 186,026. FOOD & AG INITIATIVES EXPENSES -105,312. CBI LOBBYING FUND EXPENSE -425,500. PART XII, LINE 2D - OTHER ADJUSTMENTS: CBI 53,903. CBI LOBBYING FUND 425,500. FOOD & AG INITIATIVES REVENUE 186,026. PART XII, LINE 4B - OTHER ADJUSTMENTS: LOSS ON DISPOSAL OF FIXED ASSETS -57,374. PART XIII, LINE 2D - OTHER ADJUSTMENTS: FOOD & AG INITIATIVES EXPENSES 105,312. LOSS ON DISPOSAL OF ASSETS 57,374. CBI LOBBYING FUND 425,500. EUROPE 0 1 PROGRAM SERVICES CONFERENCE 83887 EAST ASIA AND THE PACIFIC 0 2 PROGRAM SERVICES CONFERENCE 515701 INDIA 0 3 PROGRAM SERVICES CONFERENCE 342725 6 0 6 942313 0 942313 0 0 0 0 0 0 METHOD USED TO ACCCOUNT FOR EXPENDITURES: SCHEDULE F, PART I, LINE 3: EXPENDITURES ARE ACCOUNTED FOR ON THE ACCRUAL BASIS X X X 1 1 X X X X X 0 1 0 GREENWOOD JAMES 799064 0 360000 0 0 0 319926 0 77996 0 1556986 0 0 0 MURPHY EARLY LISA 371754 0 111195 0 0 0 29926 0 11152 0 524027 0 0 0 WHITAKER A SCOTT 525480 0 157500 0 0 0 29926 0 19816 0 732722 0 0 0 DILENGE THOMAS 357790 0 107625 0 0 0 29926 0 20737 0 516078 0 0 0 EISENBERG ALAN 364248 0 129769 0 0 0 29926 0 20467 0 544410 0 0 0 DEL MONTE BRENT 339498 0 101706 0 0 0 29926 0 12038 0 483168 0 0 0 ERICKSON BRENT 311377 0 65000 0 0 0 29926 0 18927 0 425230 0 0 0 BOMER SHARON 228969 0 45000 0 0 0 29711 0 21870 0 325550 0 0 0 JOSEPH JEFFREY 293689 0 88791 0 0 0 26251 0 21133 0 429864 0 0 0 FINAN AMY 256340 0 78000 0 0 0 29808 0 12659 0 376807 0 0 0 LYCETT ROBERTA 252535 0 76280 0 0 0 29926 0 16758 0 375499 0 0 0 RADCLIFFE SARA 285866 0 60000 0 0 0 29926 0 12193 0 387985 0 0 0 DARRAGH SEAN 314720 0 94500 0 0 0 29926 0 20626 0 459772 0 0 0 KELLY PATRICK 236470 0 70725 0 0 0 29788 0 15518 0 352501 0 0 0 DENNIS SANDRA 261004 0 16500 0 0 0 29926 0 15518 0 322948 0 0 0 SAUER HANSJORG 242171 0 17500 0 0 0 27913 0 15518 0 303102 0 0 0 MCHUGH PETER 205153 0 16500 0 0 0 27291 0 15518 0 264462 0 0 0 PART I, LINE 1A FIRST CLASS OR CHARTER TRAVEL -- JAMES GREENWOOD $11,653 NOT INCLUDED IN INCOME FIRST CLASS OR CHARTER TRAVEL -- ALAN EISENBERG $1,511 NOT INCLUDED IN INCOME FIRST CLASS OR CHARTER TRAVEL -- SEAN DARRAGH $5,897 NOT INCLUDED IN INCOME TRAVEL FOR COMPANIONS -- JAMES GREENWOOD $6,215 NOT INCLUDED IN INCOME HEALTH OR SOCIAL CLUB DUES -- ALAN EISENBERG $780 NOT INCLUDED IN INCOME PART I, LINE 4B JAMES GREENWOOD 457(F) PLAN $290,000 FORM 990, PART VI, SECTION A, LINE 1 THE BOARD OF DIRECTORS SHALL DESIGNATE, BY RESOLUTION AND WITH A QUORUM PRESENT, NOT MORE THAN NINETEEN (19) DIRECTORS OF THE BOARD TO ACT AS AN EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE SHALL CONSIST OF THE SEVEN (7) ELECTED OFFICERS OF THE ORGANIZATION (AS DEFINED IN ARTICLE VIII); THE IMMEDIATE PAST CHAIR OF THE ORGANIZATION; THE VICE CHAIRS OF EACH SECTION'S GOVERNING BOARD; AND THE BALANCE BEING AT-LARGE DIRECTORS FROM THE FULL BOARD. IF THE IMMEDIATE PAST CHAIR IS NO LONGER ELIGIBLE TO SERVE ON THE FULL BOARD, AN ADDITIONAL AT-LARGE DIRECTOR FROM THE FULL BOARD SHALL BE SELECTED FOR THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE SHALL HAVE, AND BE AUTHORIZED TO EXERCISE, ALL POWERS OF THE FULL BOARD, EXCEPT: (A) THE POWER TO ELECT OR REMOVE ELECTED OFFICERS OR DIRECTORS, TO CHANGE THE SIZE OF THE BOARD, TO CHANGE ELIGIBILITY, QUALIFICATIONS OR RIGHTS OF MEMBERSHIP, TO APPROVE THE FINANCIAL BUDGET FOR THE ORGANIZATION, OR TO MAKE DETERMINATIONS AS TO DIRECTOR AND OFFICER COMPENSATION, WHERE APPLICABLE; AND (B) THE POWER TO AMEND THE ARTICLES OF INCORPORATION OR THE BYLAWS OF THE ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 2 BASED ON A RESPONSE TO A SURVEY DISTRIBUTED TO EACH MEMBER OF BIOTECHNOLOGY INDUSTRY ORGANIZATION'S BOARD OF DIRECTORS, FIVE MEMBERS OF THE BOARD -- MAXINE GOWEN, DAVID HALE, DAVID PYOTT, JONATHAN WOLFSON AND SCOTT KOENIG -- INDICATED BUSINESS RELATIONSHIPS WITH OTHER MEMBERS OF THE BOARD. FORM 990, PART VI, SECTION A, LINE 4 THE BYLAWS FOR BIOTECHNOLOGY INDUSTRY ORGANIZATION WERE MODIFIED TWICE IN 2010. FIRST, IN MAY 2010, THE BYLAWS WERE MODIFIED TO CREATE NO MORE THAN TWO "CHAIR EMERITUS" POSITIONS ON THE BOARD. SECOND, IN DECEMBER 2010, THE BYLAWS WERE MODIFIED TO ADD A NEW SUBCATEGORY OF "CORE MEMBER" TO ALLOW FOR A NEW GROUPING KNOWN AS "NON-DOMESTIC COMPANIES." FORM 990, PART VI, SECTION A, LINE 6 THE MEMBERS OF THE ORGANIZATION SHALL BE DIVIDED INTO FOUR CLASSES; CORE MEMBERS, ASSOCIATE MEMBERS, AFFILIATE MEMBERS, AND CENTER MEMBERS, DEFINED AS FOLLOWS: (A) CORE MEMBERS - ANY CORPORATION, PARTNERSHIP, ASSOCIATION, OR OTHER ENTITY ORGANIZED FOR PROFIT, A SUBSTANTIAL PERCENTAGE OF WHOSE BUSINESS ACTIVITIES INVOLVE BIOTECHNOLOGY, GENOMICS, BIOINFORMATICS OR RELATED NEW TECHNOLOGIES, IS ELIGIBLE FOR MEMBERSHIP. CORE MEMBERS ARE THOSE ENTITIES THAT UTILIZE BIOTECHNOLOGY, GENOMICS, BIOINFORMATICS OR OTHER RELATED NEW TECHNOLOGIES IN RESEARCH, DEVELOPMENT, TESTING, MANUFACTURING, OR SALES OF PRODUCT OR INFORMATION, AS WELL AS OTHER FIRMS THE BOARD SO CHARACTERIZES AND PLACES IN THIS CATEGORY. CORE MEMBERS SHALL BE GROUPED IN THE FOLLOWING SUBCATEGORIES: (I) EMERGING COMPANIES, WHICH ARE FIRMS THAT EMPLOY LESS THAN 350 PERSONS AND THAT DO NOT HAVE A THERAPEUTIC OR DIAGNOSTIC PRODUCT APPROVED FOR SALE IN THE U.S. MARKET; (II) ESTABLISHED FIRMS, WHICH ARE THOSE FIRMS THAT EMPLOY 350 OR MORE PERSONS OR THAT HAVE A THERAPEUTIC OR DIAGNOSTIC PRODUCT APPROVED FOR SALE IN THE U.S. MARKET; (III) LARGE FIRMS, WHICH ARE ESTABLISHED FIRMS THAT HAVE ANNUAL WORLDWIDE SALES OF BIOTECHNOLOGY PRODUCTS IN EXCESS OF $1.5 BILLION; (IV) NON-DOMESTIC COMPANIES, WHICH ARE CORE MEMBERS WITHOUT SIGNIFICANT OPERATIONS IN THE UNITED STATES OR SIGNIFICANT COLLABORATIONS WITH A U.S. ENTITY. (B) ASSOCIATE MEMBERS - ANY CORPORATION, PARTNERSHIP, ASSOCIATION, OR OTHER ENTITY ORGANIZED FOR PROFIT, A SUBSTANTIAL PORTION OF WHOSE ACTIVITIES INVOLVE PROVIDING SERVICES OR PRODUCTS OF BENEFIT TO COMPANIES WHOSE PRINCIPAL BUSINESS IS BIOTECHNOLOGY, IS ELIGIBLE FOR ASSOCIATE MEMBERSHIP. ASSOCIATE MEMBERS ARE THOSE COMMERCIAL ENTITIES WHICH DO NOT NECESSARILY UTILIZE BIOTECHNOLOGY; E.G. TECHNICAL SUPPORT, EQUIPMENT, CONSTRUCTION, ACCOUNTING, AND LAW FIRMS THAT SERVICE THE BIOTECHNOLOGY INDUSTRY, AS WELL AS OTHER FIRMS THAT THE BOARD CHARACTERIZES AND PLACES IN THIS CATEGORY; (C) AFFILIATE MEMBERS - ANY GOVERNMENTAL OR NONPROFIT ENTITY OR COUNTRY, STATE OR REGIONAL INDUSTRY, TRADE OR PROFESSIONAL ASSOCIATION WITH AN INTEREST IN, OR A MANDATE TO PROMOTE THE DEVELOPMENT OF, BIOTECHNOLOGY IS ELIGIBLE FOR AFFILIATE MEMBERSHIP. THERE SHALL BE NO SIZE TESTS APPLIED TO AFFILIATE MEMBER APPLICANTS; (D) CENTER MEMBERS - ANY INSTITUTION, NOT GENERALLY ELIGIBLE FOR CORE MEMBERSHIP, THAT IS SPONSORED BY A STATE, REGION OR ACADEMIC INSTITUTION AND WORKS IN SUPPORT OF COMMERCIAL BIOTECHNOLOGY MAY BE ELIGIBLE FOR CONSIDERATION AS A CENTER MEMBER. FORM 990, PART VI, SECTION A, LINE 7A FOR EACH SECTION IN WHICH THE MEMBER PARTICIPATES, EACH MEMBER SHALL HAVE THE RIGHT TO VOTE ON THE ELECTION OF DIRECTORS FOR THE SECTION GOVERNING BOARD, BUT SHALL HAVE NO OTHER VOTING RIGHTS EXCEPT ON MATTERS BROUGHT TO THE MEMBERSHIP BY ANY SUCH GOVERNING BOARD OR THE ORGANIZATION'S BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 AND RELATED SCHEDULES ARE PREPARED BY THE ORGANIZATION'S CERTIFIED PUBLIC ACCOUNTANTS UNDER THE GUIDANCE OF THE CFO. THE CFO AND THE CONTROLLER THOROUGHLY REVIEW ALL CALCULATIONS AND SCHEDULES TO CONFIRM THEY REFLECT THE ACTUAL FINANCIAL RESULTS OF THE ORGANIZATION. THE COMPLETE FORM 990 IS THEN REVIEWED INTERNALLY BY THE CEO, COO, CFO AND CONTROLLER IN CONSULTATION WITH LEGAL COUNSEL AND, AS APPROPRIATE, FURTHER CONSULTATION WITH THE ORGANIZATION'S CERTIFIED PUBLIC ACCOUNTANTS. FINALLY, THE FORM 990 IS PROVIDED TO THE CHAIRMAN OF THE BOARD FOR REVIEW, QUESTIONS AND/OR COMMENTS, AND THEN SENT TO THE BIOTECHNOLOGY INDUSTRY ORGANIZATION EXECUTIVE COMMITTEE MEMBERS FOR THEIR REVIEW, QUESTIONS AND/OR COMMENTS AS WELL. ALL REVIEWS ARE COMPLETED BEFORE THE FORM IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C BIOTECHNOLOGY INDUSTRY ORGANIZATION TAKES SEVERAL STEPS TO ADDRESS COMPLIANCE BY EMPLOYEES AND DIRECTORS WITH ITS CONFLICTS OF INTEREST POLICY. BIOTECHNOLOGY INDUSTRY ORGANIZATION TRAINS ALL NEW EMPLOYEES AND DIRECTORS ON VARIOUS ASPECTS OF BIOTECHNOLOGY INDUSTRY ORGANIZATION'S COMPLIANCE PROGRAM, INCLUDING CONFLICTS OF INTEREST, AND BIOTECHNOLOGY INDUSTRY ORGANIZATION'S WRITTEN CONFLICTS OF INTEREST POLICY REQUIRES ALL EMPLOYEES TO DISCLOSE ANY OUTSIDE PERSONAL BUSINESS INTERESTS TO THEIR SUPERVISOR. BIOTECHNOLOGY INDUSTRY ORGANIZATION'S GENERAL COUNSEL REGULARLY ADVISES BIOTECHNOLOGY INDUSTRY ORGANIZATION'S EXECUTIVES AND SUPERVISORS ON SUCH MATTERS. BIOTECHNOLOGY INDUSTRY ORGANIZATION ALSO CONTRACTS WITH AN INDEPENDENT ORGANIZATION TO PROVIDE EMPLOYEES AND OTHERS WITH THE ABILITY TO FILE ANONYMOUS REPORTS CONCERNING THE VIOLATION OF ANY LAWS OR BIOTECHNOLOGY INDUSTRY ORGANIZATION POLICIES, INCLUDING ALLEGATIONS OF POTENTIAL CONFLICTS OF INTEREST, AND BIOTECHNOLOGY INDUSTRY ORGANIZATION HAS A PROCESS IN PLACE TO FOLLOW UP ON ANY SUCH COMPLAINTS IN A TIMELY AND THOROUGH MANNER. FURTHER, BIOTECHNOLOGY INDUSTRY ORGANIZATION UNDERTAKES A QUESTIONNAIRE SENT TO EACH MEMBER OF ITS BOARD OF DIRECTORS SEEKING DISCLOSURE OF ANY POTENTIAL CONFLICTS OF INTERESTS THEY MAY HAVE, OR THEIR FAMILY MEMBERS MAY HAVE, ASSOCIATED WITH BUSINESSES OR ORGANIZATIONS THAT DO BUSINESS WITH BIOTECHNOLOGY INDUSTRY ORGANIZATION. POTENTIAL CONFLICTS ARE MONITORED AND REVIEWED AT THE MANAGEMENT AND SENIOR MANAGEMENT LEVEL OF THE ORGANIZATION, AND DEPENDING ON THE CONFLICT, DETERMINATIONS MAY BE MADE AT THE BOARD OR SENIOR MANAGEMENT LEVEL. A CONFLICT MAY RESULT IN RECUSAL OR OTHER APPROPRIATE RESTRICTIONS ON THE INDIVIDUAL'S PARTICIPATION OR ACTIVITIES WITHIN BIOTECHNOLOGY INDUSTRY ORGANIZATION, INCLUDING WHERE APPROPRIATE TERMINATION. FORM 990, PART VI, SECTION B, LINE 15 IN 2008, THE EXECUTIVE AGREEMENT FOR THE PRESIDENT AND CEO OF BIOTECHNOLOGY INDUSTRY ORGANIZATION WAS RENEGOTIATED AND RENEWED. THE COMPENSATION HE RECEIVED IS DETAILED THROUGH THIS EXECUTIVE AGREEMENT. THE BIOTECHNOLOGY INDUSTRY ORGANIZATION EXECUTIVE COMMITTEE, WHICH IS COMPRISED OF INDEPENDENT BIOTECHNOLOGY INDUSTRY ORGANIZATION BOARD MEMBERS, LEADS AND UNDERTAKES THIS PROCESS. THE MEMBERS OF THE EXECUTIVE COMMITTEE WERE ASSISTED AND COUNSELED, CONTEMPORANEOUSLY, BY BOTH INDEPENDENT OUTSIDE LEGAL COUNSEL WHO IS AN EXPERT IN THIS AREA OF THE LAW, AND AN INDEPENDENT OUTSIDE CONSULTANT THAT PROVIDED BENCHMARKING SERVICES AND INFORMATION ON EXECUTIVE COMPENSATION ISSUES. THE BIOTECHNOLOGY INDUSTRY ORGANIZATION EXECUTIVE COMMITTEE, IN CONSULTATION WITH THE FULL BOARD, APPROVED THE EXECUTIVE AGREEMENT FOR THE BIOTECHNOLOGY INDUSTRY ORGANIZATION PRESIDENT AND CEO. IN 2010, THE BIOTECHNOLOGY INDUSTRY ORGANIZATION EXECUTIVE COMMITTEE EVALUATED THE PERFORMANCE OF THE BIOTECHNOLOGY INDUSTRY ORGANIZATION PRESIDENT AND CEO UNDER THIS EXECUTIVE AGREEMENT, AND BASED ON THIS PERFORMANCE EVALUATION, DETERMINED THE APPROPRIATE AMOUNT FOR THE DISCRETIONARY COMPONENT OF HIS COMPENSATION FOR THAT YEAR. FORM 990, PART VI, SECTION B, LINE 15B: DECISIONS REGARDING THE COMPENSATION FOR OFFICERS AND KEY EMPLOYEES OF THE ORGANIZATION ARE NEGOTIATED INDIVIDUALLY AND ARE PERFORMANCE-BASED, IN ACCORDANCE WITH AN ANNUAL WRITTEN EVALUATION PROCESS THAT HAS BEEN ESTABLISHED FOR ALL EMPLOYEES OF THE ORGANIZATION. THE CHIEF OPERATING OFFICER LEADS AND UNDERTAKES THIS PROCESS, IN COORDINATION WITH THE PRESIDENT & CEO. AN INDEPENDENT CONSULTANT PROVIDES COMPARATIVE BENCHMARKING SERVICES FOR SENIOR MANAGEMENT POSITIONS, AND OTHER INFORMATION ON COMPENSATION ISSUES, TRENDS, POLICIES, AND BEST PRACTICES FOR USE BY THE ORGANIZATION. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: NET UNREALIZED GAINS ON INVESTMENTS: 151,633. CBI REVENUE 53,903. CBI LOBBYING FUND REVENUE 425,500. FOOD & AG INITIATIVES REVENUE 186,026. FOOD & AG INITIATIVES EXPENSES -105,312. CBI LOBBYING FUND EXPENSE -425,500. TOTAL TO FORM 990, PART XI, LINE 5: 286,250.